Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.

od Kawakami, Koji, Husain, Syed R., Kawakami, Mariko, Puri, Raj K.
Izdano 2002

Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models

od Nakashima, Hideyuki, Fujisawa, Toshio, Husain, Syed R, Puri, Raj K
Izdano 2010

Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma

od Han, Jing, Fujisawa, Toshio, Husain, Syed R, Puri, Raj K
Izdano 2014

Current Status of Multipotent Mesenchymal Stromal Cells

od Husain, Syed R., Ohya, Yoshikazu, Toguchida, Junya, Puri, Raj K.
Izdano 2014

In Vivo Overexpression of IL-13 Receptor α2 Chain Inhibits Tumorigenicity of Human Breast and Pancreatic Tumors in Immunodeficient Mice

od Kawakami, Koji, Kawakami, Mariko, Snoy, Philip J., Husain, Syed R., Puri, Raj K.
Izdano 2001

A Novel Combination Immunotherapy for Cancer by IL-13Rα2–Targeted DNA Vaccine and Immunotoxin in Murine Tumor Models

od Nakashima, Hideyuki, Terabe, Masaki, Berzofsky, Jay A., Husain, Syed R., Puri, Raj K.
Izdano 2011

Generation of interleukin-13 receptor alpha2 antigen expressing modified vaccinia ankara recombinant virus for potential cancer immunotherapy

od Sato, Yuki, Vatsan, Ramjay, Joshi, Bharat H, Husain, Syed R, Puri, Raj K
izdano v J Immunother Cancer (2014)

Immunomodulatory Effects of Interferons in Malignancies

od Bekisz, Joseph, Sato, Yuki, Johnson, Chase, Husain, Syed R., Puri, Raj K., Zoon, Kathryn C.
Izdano 2013

Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling

od Hall, Bradford, Nakashima, Hideyuki, Sun, Zhi-Jun, Sato, Yuki, Bian, Yansong, Husain, Syed R, Puri, Raj K, Kulkarni, Ashok B
Izdano 2013

Specific Targeting of Human Interleukin (IL)-13 Receptor α2-Positive Cells with Lentiviral Vectors Displaying IL-13

od Ou, Wu, Marino, Michael P., Suzuki, Akiko, Joshi, Bharat, Husain, Syed R., Maisner, Andrea, Galanis, Evanthia, Puri, Raj K., Reiser, Jakob
Izdano 2012

Potent Antitumor Effects of Combination Therapy With IFNs and Monocytes in Mouse Models of Established Human Ovarian and Melanoma Tumors

od Nakashima, Hideyuki, Miyake, Kotaro, Clark, Christopher R, Bekisz, Joseph, Finbloom, Joel, Husain, Syed R., Baron, Samuel, Puri, Raj K., Zoon, Kathryn C.
Izdano 2011

Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer

od Green, Daniel S, Husain, Syed R, Johnson, Chase L, Sato, Yuki, Han, Jing, Joshi, Bharat, Hewitt, Stephen M, Puri, Raj K, Zoon, Kathryn C
izdano v Immunotherapy (2019)

Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation

od Vatsan, Ramjay S, Bross, Peter F, Liu, Ke, Theoret, Marc, De Claro, Angelo R, Lu, Jinhua, Helms, Whitney, Niland, Brian, Husain, Syed R, Puri, Raj K
Izdano 2013

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma(†)

od Kunwar, Sandeep, Chang, Susan, Westphal, Manfred, Vogelbaum, Michael, Sampson, John, Barnett, Gene, Shaffrey, Mark, Ram, Zvi, Piepmeier, Joseph, Prados, Michael, Croteau, David, Pedain, Christoph, Leland, Pamela, Husain, Syed R., Joshi, Bharat H., Puri, Raj K.
Izdano 2010